MedTrace Logo

Neurobiological Markers of Treatment Response for Anxiety and OCD

NCT05663489 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-12-23

No results posted yet for this study

Summary

Obsessive-compulsive disorder (OCD) and anxiety disorders are common and debilitating conditions which are often chronic when treatment is not provided. International guidelines recommend cognitive behavioral therapy (CBT) as the first-line treatment, and research has shown that CBT can be delivered over a concentrated period of time. The Bergen 4-Day Treatment (B4DT) is an exposure-based treatment which is delivered over four consecutive days. B4DT has been shown to induce rapid and long-lasting remission in around 70% of patients. This provides a platform for studying psychological and neurobiological changes associated with treatment response and non-response. The present study will investigate longitudinal changes in psychological measures and DNA methylation in patients who receive the B4DT, as well as a subset will also undergo multimodal brain imaging.

Conditions

Interventions

BEHAVIORAL

Bergen 4-Day Treatment (B4DT)

A concentrated and exposure-based psychological treatment over four consecutive days

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • Harvard Medical School (HMS and HSDM)

    collaborator OTHER

  • University of Bergen

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Bjarne Hansen, PhD · Haukeland University Hospital

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-23
Primary Completion
2024-08-01
Completion
2027-12-11

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05663489 on ClinicalTrials.gov